
Xlife Sciences develops and commercializes early-stage life sciences research by founding and funding a company for each project.
xlifesciences.chCrawled Nov 13, 2026
Xlife Sciences AG portfolio companies applying artificial intelligence to drug discovery, diagnostics, and life sciences workflows.
Xlife Sciences AG biotech and therapeutics portfolio, advancing novel treatments across oncology, immunology, and rare disease.
Xlife Sciences AG portfolio companies developing medical devices, diagnostics, and surgical innovations across early-stage MedTech.
Xlife Sciences AG portfolio of enabling technology platform companies, building infrastructure for next-generation life sciences research and care.
Ad hoc disclosures and price-sensitive announcements from Xlife Sciences AG, published in line with SIX Swiss Exchange requirements.
Latest news about Xlife Sciences AG.
Latest corporate press releases and ad hoc disclosures from Xlife Sciences AG and its early-stage life sciences and AI portfolio companies.
Press releases, ad hoc disclosures, media coverage, and downloadable assets for journalists and analysts following Xlife Sciences AG.
Board of directors, executive management, articles of association, and corporate governance structure for Xlife Sciences AG.
How Xlife Sciences AG embeds sustainability into portfolio selection, governance, and operations across its early-stage life sciences investments.
Annual and half-year reports, key financial figures, and portfolio performance for Xlife Sciences AG, the Swiss-listed life sciences investment holding.
Investor relations contact details for Xlife Sciences AG. Questions on the share, financials, and upcoming events go directly to the IR team.
Xlife Sciences AG is a Swiss-listed holding investing in early-stage AI, MedTech, biotech, and tech platforms. Financials, equity story, ad hoc news.
How Xlife Sciences AG collects, processes, and protects personal data on this website, in line with Swiss and European data protection laws.
VERAXA Biotech (VRXA) is progressing its oncology-focused drug pipeline following its Nasdaq listing in June 2026. Xlife Sciences AG has released its first-half performance update, though specific details remain undisclosed. Both companies are active in the biotech and life sciences sectors, with VRXA emphasizing cancer therapies.
Sep 2026NewMediaWireNews article
VERAXA Biotech AG (NASDAQ: **VRXA**) accelerates its oncology drug development following its Nasdaq listing. Parent company **Xlife Sciences (SIX: XLS)** reports progress in its first-half operations, though specific pipeline details remain undisclosed. The move positions VERAXA to expand its cancer-focused research portfolio.
Sep 2026FinancialContentNews article
VERAXA Biotech begins trading on Nasdaq under the ticker **VRXA** after completing a business combination with Voyager Acquisition Corp. The company, a portfolio asset of Xlife Sciences AG, focuses on developing advanced cancer therapies. This move marks its transition to a publicly traded entity, enabling broader access to capital for its research pipeline.
Jun 2026The Daily Tribune NewsNews article
Xlife Sciences AG moves to the Main Segment of the SIX Swiss Exchange to enhance its visibility and credibility in the market. The company aims to solidify its position through this strategic listing upgrade, aligning with stricter regulatory and transparency standards. This transition reflects the firm’s growth ambitions and commitment to investor confidence.
Dec 2025ad-hoc-news.deNews article